Ekso Bionics to Present at the Groundbreak 2017 Construction Conference
RICHMOND, Calif., March 27, 2017 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO), a robotic exoskeleton company, today announced that Russ Angold, the company’s co-founder and chief technology officer, will be a presenter at the ProCore Groundbreak 2017 construction technology conference being held in Austin, Texas on March 29-31, 2017.
During the ProCore annual conference, which attracts roughly 2,000 attendees, Ekso Bionics will demonstrate the EksoZeroG, a lightweight assistive device that has been designed to bear the load of heavy tools and enhance both safety and productivity for workers at construction sites. A preview and hands-on demonstration of additional new exoskeleton technology to aid in overhead work will also be provided by Ekso Bionics.
“We are excited to demonstrate our technology at Groundbreak and to generate awareness of our innovative construction technology, which makes work sites safer and workers more productive,” said Angold. “We are optimistic that conference attendees will leave the conference wanting to integrate EksoZeroG technology on their own jobsites.”
Angold’s brother, Ryan Angold, who himself suffered a spinal cord injury, will discuss firsthand how to overcome life’s challenges and will co-present.
Presentation: “Techno-geekery: Construction turns sci-worthy”
Thursday, March 30th, 2:45- 3:35pm, Mainstage
“I am so pleased with the progress we have made in advancing our technologies for the industrial market and am excited to showcase the EksoZeroG at Groundbreak 2017,” said Thomas Looby, president and chief executive officer of Ekso Bionics. “Leveraging our extensive IP, we are making advances that we believe will change lives around the world, in both the medical and industrial arenas.”
Ekso Bionics will also take part in the following upcoming industrial trade shows:
- The Rise of the Machines Conference
- April 6th, Chicago
- RIMS Annual Conference & Exhibition
- April 23rd- 26th, Philadelphia
- COLLISION Tech Conference
- May 2nd-4th, New Orleans
- The International Rental Exposition
- May 2nd-4th, Amsterdam
To learn more, visit www.eksobionics.com.
About Ekso Bionics®
Ekso Bionics is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical, industrial and defense applications. Founded in 2005, the company continues to build upon its unparalleled expertise to design some of the most cutting-edge, innovative wearable robots available on the market. Ekso Bionics is the only exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe, to providing research for the advancement of R&D projects intended to benefit U.S. defense capabilities. The company is headquartered in the Bay Area and is listed on the Nasdaq Capital Market under the symbol EKSO. For more information, visit: www.eksobionics.com.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons, (ii) estimates or projection of financial results, financial condition, capital expenditures, capital structure or other financial items, (iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing to fund the Company's operations and necessary to develop or enhance our technology, the significant length of time and resources associated with the development of the Company's products, the Company's failure to achieve broad market acceptance of the Company's products, the failure of our sales and marketing organization or partners to market our products effectively, adverse results in future clinical studies of the Company's medical device products, the failure to obtain or maintain patent protection for the Company's technology, failure to obtain or maintain regulatory approval to market the Company's medical devices, lack of product diversification, existing or increased competition, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. To learn more about Ekso Bionics please visit us at www.eksobionics.com. The Company does not undertake to update these forward-looking statements.
Ekso Bionics Media Contact: Carrie Yamond 917-371-2320 email@example.com Ekso Bionics Investor Contact: Debbie Kaster 415-937-5403 firstname.lastname@example.org
Released March 27, 2017